Jean-Christophe Tille
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean-Christophe Tille has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Alexandre Bodmer
Oncogynecology Unit; Geneva University Hospitals; Geneva Switzerland
2 shared publicationsAlexandre Rozenholc
Surgical Senology Unit; Geneva University Hospitals; Geneva Switzerland
2 shared publicationsJean-François Egger
Viollier Weintraub Laboratory; Viollier AG; Geneva Switzerland
2 shared publicationsMarie-Françoise Pelte
Department of Genetics and Laboratory Medicine, Division of Clinical Pathology, University Hospital of Geneva, 1211 Geneva 4, Switzerland
2 shared publications- Michael Möller
School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva 1221 , Switzerland
2 shared publications Monica Castiglione
Oncogynecology Unit; Geneva University Hospitals; Geneva Switzerland
2 shared publications
Latest Publications
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e260031
Quantitative Diffusion-weighted Imaging in Eosinophilic Solid and Cystic Renal Cell Carcinoma
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e260031
Quantitative Diffusion-weighted Imaging in Eosinophilic Solid and Cystic Renal Cell Carcinoma
- Open Access
- 27 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1269
Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma
Background/Objectives: Despite recent therapeutic advances, the clinical management of renal cell carcinoma (RCC) remains suboptimal. Current treatments are hindered by limited efficacy, the emergence of acquired drug resistance, suboptimal tolerability, and a lack of tumor-specific targeting. While development of novel agents remains an important avenue, it is often constrained by high costs, long development time, and low success rates. As an alternative approach, drug combinations of approved agents offer a promising strategy. Methods: Using our proprietary drug combination methodology, we identified multidrug combinations in RCC cells representing the clear cell (786O) and sarcomatoid chromophobe (UOK276) histological subtypes of RCC. Results: From an initial panel of 10 drugs, either approved or undergoing clinical trial, the optimized drug combinations (ODCs) contained crizotinib, telaglenastat, U-104, and vismodegib at clinical and subtherapeutic doses. The ODCs were non-toxic in advanced hepatic, renal, and cardiac cellular models. Importantly, their anti-tumor activity, already notable in normoxic (21% O2) conditions (approx. 50%) was markedly enhanced in tumor-relevant hypoxia (1.5% O2), reaching up to 77% in 2D and 62% in 3D spheroid 786O models. Moreover, chronic exposure of 786O and UOK276 cells led to durable responses, suggesting a prolonged effect in responders. Conclusions: Our findings demonstrate the potential of optimized, non-toxic drug combinations as a highly selective and effective strategy for accelerating the development of precision RCC treatment.
- 27 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1269
Open AccessRational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma
Background/Objectives: Despite recent therapeutic advances, the clinical management of renal cell carcinoma (RCC) remains suboptimal. Current treatments are hindered by limited efficacy, the emergence of acquired drug resistance, suboptimal tolerability, and a lack of tumor-specific targeting. While development of novel agents remains an important avenue, it is often constrained by high costs, long development time, and low success rates. As an alternative approach, drug combinations of approved agents offer a promising strategy. Methods: Using our proprietary drug combination methodology, we identified multidrug combinations in RCC cells representing the clear cell (786O) and sarcomatoid chromophobe (UOK276) histological subtypes of RCC. Results: From an initial panel of 10 drugs, either approved or undergoing clinical trial, the optimized drug combinations (ODCs) contained crizotinib, telaglenastat, U-104, and vismodegib at clinical and subtherapeutic doses. The ODCs were non-toxic in advanced hepatic, renal, and cardiac cellular models. Importantly, their anti-tumor activity, already notable in normoxic (21% O2) conditions (approx. 50%) was markedly enhanced in tumor-relevant hypoxia (1.5% O2), reaching up to 77% in 2D and 62% in 3D spheroid 786O models. Moreover, chronic exposure of 786O and UOK276 cells led to durable responses, suggesting a prolonged effect in responders. Conclusions: Our findings demonstrate the potential of optimized, non-toxic drug combinations as a highly selective and effective strategy for accelerating the development of precision RCC treatment.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Pathology
- Vol. 2025 (1) , 4514707
Fallopian Tube’s Placental Site Nodule: A Case Report
Introduction: Placental site nodules (PSNs) are uncommon lesions typically found in uterine specimens and extremely rarely in extrauterine locations such as the fallopian tubes. PSNs are usually discovered incidentally and result from prior implantation sites. This case report describes an unexpected PSN found in a fallopian tube during a cesarean section with concurrent tubal sterilization. Case Presentation: A 38‐year‐old multiparous woman (gravida 4, para 2) with a previous vaginal delivery underwent tubal sterilization during a cesarean section. The surgical procedure was uneventful, with no macroscopic abnormalities noted. The patient’s medical history included treatment for an ectopic pregnancy with methotrexate. Pathological examination revealed the right fallopian tube to be unremarkable. However, the left fallopian tube contained a 0.3 cm nodule within its wall, characterized by central hyalinization, dystrophic calcifications, and peripheral intermediate trophoblast cells. Immunohistochemical analysis demonstrated GATA3 positivity and a low proliferative index (MIB‐1). The absence of mitotic activity, necrosis, and typical morphology confirmed the diagnosis of a PSN. Discussion: PSNs are benign lesions derived from intermediate extravillous trophoblasts. Their identification relies on both morphological characteristics and immunohistochemical staining. The differential diagnosis includes various trophoblastic diseases, which can be distinguished from PSNs by their specific features. This case contributes to the limited literature on extrauterine PSNs, highlighting the importance of recognizing these lesions in atypical locations and differentiating them from pathologies that are more aggressive. Conclusion: This case highlights the rarity of PSNs in the fallopian tubes and underscores the importance of comprehensive pathological analysis for an accurate diagnosis.
- 1 January 2025
- Published by Wiley in Case Reports in Pathology
- Vol. 2025 (1) , 4514707
Open AccessFallopian Tube’s Placental Site Nodule: A Case Report
Introduction: Placental site nodules (PSNs) are uncommon lesions typically found in uterine specimens and extremely rarely in extrauterine locations such as the fallopian tubes. PSNs are usually discovered incidentally and result from prior implantation sites. This case report describes an unexpected PSN found in a fallopian tube during a cesarean section with concurrent tubal sterilization. Case Presentation: A 38‐year‐old multiparous woman (gravida 4, para 2) with a previous vaginal delivery underwent tubal sterilization during a cesarean section. The surgical procedure was uneventful, with no macroscopic abnormalities noted. The patient’s medical history included treatment for an ectopic pregnancy with methotrexate. Pathological examination revealed the right fallopian tube to be unremarkable. However, the left fallopian tube contained a 0.3 cm nodule within its wall, characterized by central hyalinization, dystrophic calcifications, and peripheral intermediate trophoblast cells. Immunohistochemical analysis demonstrated GATA3 positivity and a low proliferative index (MIB‐1). The absence of mitotic activity, necrosis, and typical morphology confirmed the diagnosis of a PSN. Discussion: PSNs are benign lesions derived from intermediate extravillous trophoblasts. Their identification relies on both morphological characteristics and immunohistochemical staining. The differential diagnosis includes various trophoblastic diseases, which can be distinguished from PSNs by their specific features. This case contributes to the limited literature on extrauterine PSNs, highlighting the importance of recognizing these lesions in atypical locations and differentiating them from pathologies that are more aggressive. Conclusion: This case highlights the rarity of PSNs in the fallopian tubes and underscores the importance of comprehensive pathological analysis for an accurate diagnosis.
- Open Access
- 12 June 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (9) , 1568-1578
Clonal expansion of intra‐epithelial T cells in breast cancer revealed by spatial transcriptomics
The spatial distribution of tumor‐infiltrating lymphocytes (TIL) predicts breast cancer outcome and response to systemic therapy, highlighting the importance of an intact tissue structure for characterizing tumors. Here, we present ST‐FFPE, a spatial transcriptomics method for the analysis of formalin‐fixed paraffin‐embedded samples, which opens the possibility of interrogating archival tissue. The method involves extraction, exome capture and sequencing of RNA from different tumor compartments microdissected by laser‐capture, and can be used to study the cellular composition of tumor microenvironment. Focusing on triple‐negative breast cancer (TNBC), we characterized T cells, B cells, dendritic cells, fibroblasts and endothelial cells in both stromal and intra‐epithelial compartments. We found a highly variable spatial distribution of immune cell subsets among tumors. This analysis revealed that the immune repertoires of intra‐epithelial T and B cells were consistently less diverse and more clonal than those of stromal T and B cells. T‐cell receptor (TCR) sequencing confirmed a reduced diversity and higher clonality of intra‐epithelial T cells relative to the corresponding stromal T cells. Analysis of the top 10 dominant clonotypes in the two compartments showed a majority of shared but also some unique clonotypes both in stromal and intra‐epithelial T cells. Hyperexpanded clonotypes were more abundant among intra‐epithelial than stromal T cells. These findings validate the ST‐FFPE method and suggest an accumulation of antigen‐specific T cells within tumor core. Because ST‐FFPE is applicable for analysis of previously collected tissue samples, it could be useful for rapid assessment of intratumoral cellular heterogeneity in multiple disease and treatment settings.
- 12 June 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (9) , 1568-1578
Open AccessClonal expansion of intra‐epithelial T cells in breast cancer revealed by spatial transcriptomics
The spatial distribution of tumor‐infiltrating lymphocytes (TIL) predicts breast cancer outcome and response to systemic therapy, highlighting the importance of an intact tissue structure for characterizing tumors. Here, we present ST‐FFPE, a spatial transcriptomics method for the analysis of formalin‐fixed paraffin‐embedded samples, which opens the possibility of interrogating archival tissue. The method involves extraction, exome capture and sequencing of RNA from different tumor compartments microdissected by laser‐capture, and can be used to study the cellular composition of tumor microenvironment. Focusing on triple‐negative breast cancer (TNBC), we characterized T cells, B cells, dendritic cells, fibroblasts and endothelial cells in both stromal and intra‐epithelial compartments. We found a highly variable spatial distribution of immune cell subsets among tumors. This analysis revealed that the immune repertoires of intra‐epithelial T and B cells were consistently less diverse and more clonal than those of stromal T and B cells. T‐cell receptor (TCR) sequencing confirmed a reduced diversity and higher clonality of intra‐epithelial T cells relative to the corresponding stromal T cells. Analysis of the top 10 dominant clonotypes in the two compartments showed a majority of shared but also some unique clonotypes both in stromal and intra‐epithelial T cells. Hyperexpanded clonotypes were more abundant among intra‐epithelial than stromal T cells. These findings validate the ST‐FFPE method and suggest an accumulation of antigen‐specific T cells within tumor core. Because ST‐FFPE is applicable for analysis of previously collected tissue samples, it could be useful for rapid assessment of intratumoral cellular heterogeneity in multiple disease and treatment settings.
- Open Access
- 7 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9332
Genomic Instability Is an Early Event in Aluminium-Induced Tumorigenesis
Genomic instability is generally considered as a hallmark of tumorigenesis and a prerequisite condition for malignant transformation. Aluminium salts are suspected environmental carcinogens that transform mammary epithelial cells in vitro through unknown mechanisms. We report here that long-term culture in the presence of aluminium chloride (AlCl3) enables HC11 normal mouse mammary epithelial cells to form tumours and metastases when injected into the syngeneic and immunocompetent BALB/cByJ strain. We demonstrate that AlCl3 rapidly increases chromosomal structural abnormalities in mammary epithelial cells, while we failed to detect direct modulation of specific mRNA pathways. Our observations provide evidence that clastogenic activity—a well-recognized inducer of genomic instability—might account in part for the transforming abilities of aluminium in mammary epithelial cells.
- 7 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9332
Open AccessGenomic Instability Is an Early Event in Aluminium-Induced Tumorigenesis
Genomic instability is generally considered as a hallmark of tumorigenesis and a prerequisite condition for malignant transformation. Aluminium salts are suspected environmental carcinogens that transform mammary epithelial cells in vitro through unknown mechanisms. We report here that long-term culture in the presence of aluminium chloride (AlCl3) enables HC11 normal mouse mammary epithelial cells to form tumours and metastases when injected into the syngeneic and immunocompetent BALB/cByJ strain. We demonstrate that AlCl3 rapidly increases chromosomal structural abnormalities in mammary epithelial cells, while we failed to detect direct modulation of specific mRNA pathways. Our observations provide evidence that clastogenic activity—a well-recognized inducer of genomic instability—might account in part for the transforming abilities of aluminium in mammary epithelial cells.
- Open Access
- 2 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Spatial transcriptomics of tumor microenvironment in formalin-fixed paraffin-embedded breast cancer
Tumor samples are conserved in clinical practice in formalin-fixed paraffin-embedded (FFPE) blocks. Formalin fixation chemically alters nucleic acids, rendering transcriptomic analysis challenging. RNA-sequencing is usually performed on tumor bulk, without distinction of cell subtypes or location. Here we describe the development of a robust method for RNA extraction and exome-capture RNA-sequencing of laser-capture microdissected tumor cells (TC) and stromal immune cells (TIL) based on their morphology. We applied this method on 7 tumor samples (surgical or core needle biopsy) of triple-negative breast cancer (TNBC) stored in FFPE blocks over 3-10 years. Unsupervised clustering and principal component analysis showed a clear separation between gene-expression profile of TIL and TC. TIL were enriched in markers of B cells (CD79B, PAX5 and BLNK) and T cells (CD2, CD3D and CD8B) whereas tumor cells expressed epithelial markers (EPCAM, MUC1andKRT8). Microenvironment cell populations-counter (MCP)-counter deconvolution showed an enrichment in adaptive immune cell signatures in microdissected TIL. Transcripts of immune checkpoints were differentially expressed in TIL and TC. We further validated our results by qRT-PCR and multispectral immunohistochemistry. In conclusion, we showed that combining laser-capture microdissection and RNA-sequencing on archived FFPE blocks is feasible and allows spatial transcriptional characterization of tumor microenvironment.
- 2 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessSpatial transcriptomics of tumor microenvironment in formalin-fixed paraffin-embedded breast cancer
Tumor samples are conserved in clinical practice in formalin-fixed paraffin-embedded (FFPE) blocks. Formalin fixation chemically alters nucleic acids, rendering transcriptomic analysis challenging. RNA-sequencing is usually performed on tumor bulk, without distinction of cell subtypes or location. Here we describe the development of a robust method for RNA extraction and exome-capture RNA-sequencing of laser-capture microdissected tumor cells (TC) and stromal immune cells (TIL) based on their morphology. We applied this method on 7 tumor samples (surgical or core needle biopsy) of triple-negative breast cancer (TNBC) stored in FFPE blocks over 3-10 years. Unsupervised clustering and principal component analysis showed a clear separation between gene-expression profile of TIL and TC. TIL were enriched in markers of B cells (CD79B, PAX5 and BLNK) and T cells (CD2, CD3D and CD8B) whereas tumor cells expressed epithelial markers (EPCAM, MUC1andKRT8). Microenvironment cell populations-counter (MCP)-counter deconvolution showed an enrichment in adaptive immune cell signatures in microdissected TIL. Transcripts of immune checkpoints were differentially expressed in TIL and TC. We further validated our results by qRT-PCR and multispectral immunohistochemistry. In conclusion, we showed that combining laser-capture microdissection and RNA-sequencing on archived FFPE blocks is feasible and allows spatial transcriptional characterization of tumor microenvironment.
- Open Access
- 8 February 2017
- Published by Springer Nature in Reproductive Health
- Vol. 14 (1) , 1-7
Management of painful clitoral neuroma after female genital mutilation/cutting
Traumatic neuromas are the result of regenerative disorganized proliferation of the proximal portion of lesioned nerves. They can exist in any anatomical site and are responsible for neuropathic pain. Post-traumatic neuromas of the clitoris have been described as an uncommon consequence of female genital mutilation/cutting (FGM/C). FGM/C involves partial or total removal of the female genital organs for non-therapeutic reasons. It can involve cutting of the clitoris and can cause psychological, sexual, and physical complications. We aimed to evaluate the symptoms and management of women presenting with a clitoral neuroma after female genital mutilation/cutting (FGM/C). We identified women who attended our specialized clinic for women with FGM/C who were diagnosed with a traumatic neuroma of the clitoris between April 1, 2010 and June 30, 2016. We reviewed their medical files and collected socio-demographic, clinical, surgical, and histopathological information. Seven women were diagnosed with clitoral neuroma. Six attended our clinic to undergo clitoral reconstruction, and three of these suffered from clitoral pain. The peri-clitoral fibrosis was removed during clitoral reconstruction, which revealed neuroma of the clitoris in all six subjects. Pain was ameliorated after surgery. The seventh woman presented with a visible and palpable painful clitoral mass diagnosed as a neuroma. Excision of the mass ameliorated the pain. Sexual function improved in five women. One was not sexually active, and one had not yet resumed sex. Post-traumatic clitoral neuroma can be a consequence of FGM/C. It can cause clitoral pain or be asymptomatic. In the case of pain symptoms, effective treatment is neuroma surgical excision, which can be performed during clitoral reconstruction. Surgery should be considered as part of multidisciplinary care. The efficacy of neuroma excision alone or during clitoral reconstruction to treat clitoral pain should be further assessed among symptomatic women.
- 8 February 2017
- Published by Springer Nature in Reproductive Health
- Vol. 14 (1) , 1-7
Open AccessManagement of painful clitoral neuroma after female genital mutilation/cutting
Traumatic neuromas are the result of regenerative disorganized proliferation of the proximal portion of lesioned nerves. They can exist in any anatomical site and are responsible for neuropathic pain. Post-traumatic neuromas of the clitoris have been described as an uncommon consequence of female genital mutilation/cutting (FGM/C). FGM/C involves partial or total removal of the female genital organs for non-therapeutic reasons. It can involve cutting of the clitoris and can cause psychological, sexual, and physical complications. We aimed to evaluate the symptoms and management of women presenting with a clitoral neuroma after female genital mutilation/cutting (FGM/C). We identified women who attended our specialized clinic for women with FGM/C who were diagnosed with a traumatic neuroma of the clitoris between April 1, 2010 and June 30, 2016. We reviewed their medical files and collected socio-demographic, clinical, surgical, and histopathological information. Seven women were diagnosed with clitoral neuroma. Six attended our clinic to undergo clitoral reconstruction, and three of these suffered from clitoral pain. The peri-clitoral fibrosis was removed during clitoral reconstruction, which revealed neuroma of the clitoris in all six subjects. Pain was ameliorated after surgery. The seventh woman presented with a visible and palpable painful clitoral mass diagnosed as a neuroma. Excision of the mass ameliorated the pain. Sexual function improved in five women. One was not sexually active, and one had not yet resumed sex. Post-traumatic clitoral neuroma can be a consequence of FGM/C. It can cause clitoral pain or be asymptomatic. In the case of pain symptoms, effective treatment is neuroma surgical excision, which can be performed during clitoral reconstruction. Surgery should be considered as part of multidisciplinary care. The efficacy of neuroma excision alone or during clitoral reconstruction to treat clitoral pain should be further assessed among symptomatic women.
- Open Access
- 20 February 2016
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 4 (1) , 11
Histologic Assessment of Drug-Eluting Grafts Related to Implantation Site
Drug-eluting vascular prostheses represent a new direction in vascular surgery to reduce early thrombosis and late intimal hyperplasia for small calibre grafts. Subcutaneous implantation in rats is a rapid and cost-effective screening model to assess the drug-elution effect and could, to some extent, be useful to forecast results for vascular prostheses. We compared biological and histological responses to scaffolds in different implantation sites. Polycaprolactone (PCL), paclitaxel-loaded PCL (PCL-PTX) and dexamethasone-loaded PCL (PCL-DXM) electrospun scaffolds were implanted subcutaneously and in an infrarenal abdominal aortic model in rats for up to 12 weeks. At the conclusion of the study, a histological analysis was performed. Cellular graft invasion revealed differences in the progression of cellular infiltration between PCL-PTX and PCL/PCL-DXM groups in both models. Cell infiltration increased over time in the aortic model compared to the subcutaneous model for all groups. Cell counting revealed major differences in fibroblast, macrophage and giant cell graft colonisation in all groups and models over time. Macrophages and giant cells increased in the PCL aortic model; whereas in the subcutaneous model these cell types increased only after three weeks or even decreased in the drug-eluting PCL groups. Other major findings were observed only in the aortic replacement such as extracellular matrix deposition and neo-angiogenesis. The subcutaneous implant model can be used for screening, especially when drug-eluting effects are studied. However, major histological differences were observed in cell type reaction and depth of cell penetration compared to the aortic model. Our results demonstrate that the implantation site is a critical determinant of the biological response.
- 20 February 2016
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 4 (1) , 11
Open AccessHistologic Assessment of Drug-Eluting Grafts Related to Implantation Site
Drug-eluting vascular prostheses represent a new direction in vascular surgery to reduce early thrombosis and late intimal hyperplasia for small calibre grafts. Subcutaneous implantation in rats is a rapid and cost-effective screening model to assess the drug-elution effect and could, to some extent, be useful to forecast results for vascular prostheses. We compared biological and histological responses to scaffolds in different implantation sites. Polycaprolactone (PCL), paclitaxel-loaded PCL (PCL-PTX) and dexamethasone-loaded PCL (PCL-DXM) electrospun scaffolds were implanted subcutaneously and in an infrarenal abdominal aortic model in rats for up to 12 weeks. At the conclusion of the study, a histological analysis was performed. Cellular graft invasion revealed differences in the progression of cellular infiltration between PCL-PTX and PCL/PCL-DXM groups in both models. Cell infiltration increased over time in the aortic model compared to the subcutaneous model for all groups. Cell counting revealed major differences in fibroblast, macrophage and giant cell graft colonisation in all groups and models over time. Macrophages and giant cells increased in the PCL aortic model; whereas in the subcutaneous model these cell types increased only after three weeks or even decreased in the drug-eluting PCL groups. Other major findings were observed only in the aortic replacement such as extracellular matrix deposition and neo-angiogenesis. The subcutaneous implant model can be used for screening, especially when drug-eluting effects are studied. However, major histological differences were observed in cell type reaction and depth of cell penetration compared to the aortic model. Our results demonstrate that the implantation site is a critical determinant of the biological response.
- 1 June 2015
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 19 (3) , 99-102
Fourteen-year experience with the intraoperative frozen section examination of testicular lesion in a tertiary university center
- 1 June 2015
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 19 (3) , 99-102
Fourteen-year experience with the intraoperative frozen section examination of testicular lesion in a tertiary university center
- 3 December 2014
- Vol. 10 (453) , 2302-5
[Opening of the Geneva University Hospital Prostate Cancer Center].
In 2014, Geneva University Hospital has opened the first certified prostate cancer Center of western Switzerland. It incorporates 29 entities implicated in the diagnosis and treatment of this disease, thereby assuring that all available ressources are made available to patients, regardless of the division to which they were initially referred. The main strength of the Center lies in the synergy generated by its multidisciplinary tumor board. Furthermore, regular conferences, staff meetings, propectively held registers and the yearly re-certification audit support its constant quality improvement.
- 3 December 2014
- Vol. 10 (453) , 2302-5
[Opening of the Geneva University Hospital Prostate Cancer Center].
In 2014, Geneva University Hospital has opened the first certified prostate cancer Center of western Switzerland. It incorporates 29 entities implicated in the diagnosis and treatment of this disease, thereby assuring that all available ressources are made available to patients, regardless of the division to which they were initially referred. The main strength of the Center lies in the synergy generated by its multidisciplinary tumor board. Furthermore, regular conferences, staff meetings, propectively held registers and the yearly re-certification audit support its constant quality improvement.